Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Align wins China patent case against...
Regulatory patent litigation

Align wins China patent case against Angelalign

Analysis based on 9 articles · First reported Aug 12, 2026 · Last updated Aug 12, 2026

Sentiment
10
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The ruling strengthens Align's intellectual property protection in China, potentially limiting Angelalign's ability to sell infringing products in a key market. Align's stock closed 1.75% lower on the day, reflecting broader market conditions, but the decision is likely to be viewed positively for Align's competitive position.

Medical Devices Orthodontics Dental
Event Summary

On August 10, 2026, the China — Shenzhen Intermediate People s Court in China issued a first-instance judgment in favor of Align Technology in a patent infringement action against Angelalign Technology's Chinese operating subsidiaries. The court found that Angelalign's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringed Align's patent (CN113693748B) related to extraction-gap-closure technology. The court ordered Angelalign to cease using the patented technology and stop manufacturing and selling the infringing products in China, and awarded Align RMB 10 million (approximately $1.4 million) in damages. Angelalign may appeal to the China — Supreme People s Court. This ruling follows other patent-enforcement actions by Align against Angelalign, including a preliminary injunction issued by the International — Unified Patent Court in February 2026 over ClinCheck Live Update technology, and an evidentiary hearing conducted by the United States — United States International Trade Commission in July 2026 concerning five patents, with an initial determination expected in November 2026. Align continues to pursue additional patent infringement actions against Angelalign affiliates in China and Europe.

Key Actions
90 China — Shenzhen Intermediate People s Court ordered cease and desist Angelalign Technology
80 Align Technology filed patent infringement action Angelalign Technology
70 China — Shenzhen Intermediate People s Court ruled in favor Align Technology
60 International — Unified Patent Court issued preliminary injunction Angelalign Technology
50 United States — United States International Trade Commission conducted evidentiary hearing Align Technology
Entities Involved
stock
Align Technology
Align Technology is the plaintiff and beneficiary of the court ruling, which reinforces its patent portfolio and competitive position in China. The company was awarded RMB 10 million in damages and obtained an injunction against Angelalign's infringing products.
Importance 100.0 Sentiment 60.0
priv
Angelalign Technology
Angelalign Technology is the defendant and was found to infringe Align's patent. The court ordered it to cease using the patented technology and stop manufacturing and selling infringing products in China, which could impact its operations and market share.
Importance 100.0 Sentiment -60.0
govactor
China — Shenzhen Intermediate People s Court
The China — Shenzhen Intermediate People s Court issued the first-instance judgment in favor of Align, ordering Angelalign to cease infringement and awarding damages. This court's decision is a key development in the patent dispute.
Importance 80.0 Sentiment 0.0
cnt
China
China is the jurisdiction where the patent infringement case was decided. The ruling reinforces the protection of intellectual property rights in China and affects the competitive landscape in the Chinese orthodontic market.
Importance 60.0 Sentiment 0.0
govactor
International — Unified Patent Court
The International — Unified Patent Court issued a preliminary injunction in February 2026 requiring Angelalign to cease infringement of Align's ClinCheck Live Update technology, which was upheld on appeal. This is part of the broader patent enforcement actions.
Importance 50.0 Sentiment 0.0
govactor
United States — United States International Trade Commission
The United States — United States International Trade Commission conducted an evidentiary hearing in July 2026 concerning five patents asserted by Align against Angelalign. Its initial determination is expected in November 2026 and could affect imports of infringing products.
Importance 50.0 Sentiment 0.0
govactor
China — Supreme People s Court
The China — Supreme People s Court is the appellate court to which Angelalign may appeal the first-instance judgment. Its potential decision could uphold or overturn the ruling.
Importance 40.0 Sentiment 0.0
per
Joe Hogan
Joe Hogan, president and CEO of Align Technology, commented on the ruling, emphasizing the importance of intellectual property protection and Align's commitment to innovation and the Chinese market.
Importance 30.0 Sentiment 0.0
curr
China — Renminbi
The China — Renminbi is the currency in which the damages were awarded (RMB 10 million). The amount is relatively small but represents a legal victory for Align.
Importance 20.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the stock exchange where Align Technology is listed. The stock closed 1.75% lower on the day of the announcement, reflecting market reaction.
Importance 20.0 Sentiment 0.0
exch
Hong Kong Stock Exchange
The Hong Kong Stock Exchange is where Angelalign Technology is listed (6699.HK). The ruling may affect investor sentiment regarding Angelalign's stock.
Importance 20.0 Sentiment 0.0
Relationships
China — Shenzhen Intermediate People s Court related ↔ China
China related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.